SB-649868 - CAS 380899-24-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C26H24FN3O3S
Molecular Weight:
477.55
COA:
Inquire
Targets:
Orexin Receptor (OX Receptor)
Description:
SB-649868 is a novel, orally active dual orexin receptor antagonist of orexin(OX)1 and OX2 receptor (pKi=9.4 and 9.5 at the OX1 and OX2 receptor, respectively), potentially for the treatment of insomnia and sleep disorder.
Publication citing BOC Sciences Products
1. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer
2. Identification of volatiles from Pinus silvestris attractive for Monochamus galloprovincialis using a SPME-GC/MS platform
3. Use of blood clotting assays to assess potential anticoagulant rodenticide exposure and effects in free-ranging birds of prey
4. An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI
5. SWATH label-free proteomics analyses revealed the roles of oxidative stress and antioxidant defensing system in sclerotia formation of Polyporus umbellatus
6. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis

>> More

Synonyms:
N-[[(2S)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]piperidin-2-yl]methyl]-1-benzofuran-4-carboxamide; (14C)SB 649868; (14C)SB-649868; (14C)SB649868; N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide; SB 649868; SB-649868; SB649868; GSK-649868; GSK-649868; GSK649868
Solubility:
DMSO
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
Boiling Point:
725.1±55.0 ℃ at 760 Torr
Density:
1.305±0.06 g/cm3
InChIKey:
ZJXIUGNEAIHSBI-IBGZPJMESA-N
InChI:
1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1
Canonical SMILES:
CC1=NC(=C(S1)C2=CC=C(C=C2)F)C(=O)N3CCCCC3CNC(=O)C4=C5C=COC5=CC=C4
1.Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans.
Patel AX;Miller SR;Nathan PJ;Kanakaraj P;Napolitano A;Lawrence P;Koch A;Bullmore ET Psychopharmacology (Berl). 2014 Oct;231(19):3817-28. doi: 10.1007/s00213-014-3520-7. Epub 2014 Apr 26.
RATIONALE: ;The orexin-hypocretin system is important for translating peripheral metabolic signals and central neuronal inputs to a diverse range of behaviors, from feeding, motivation and arousal, to sleep and wakefulness. Orexin signaling is thus an exciting potential therapeutic target for disorders of sleep, feeding, addiction, and stress.;OBJECTIVES/METHODS: ;Here, we investigated the low dose pharmacology of orexin receptor antagonist, SB-649868, on neuroendocrine, sympathetic nervous system, and behavioral responses to insulin-induced hypoglycemic stress, in 24 healthy male subjects (aged 18-45 years; BMI 19.0-25.9 kg/m(2)), using a randomized, double-blind, placebo-controlled, within-subject crossover design. Alprazolam, a licensed benzodiazepine anxiolytic, was used as a positive comparator, as it has previously been validated using the insulin tolerance test (ITT) model in humans.;RESULTS: ;Of the primary endpoints, ITT induced defined increases in pulse rate, plasma cortisol, and adrenocorticotropic hormone in the placebo condition, but these responses were not significantly impacted by alprazolam or SB-649868 pre-treatment. Of the secondary endpoints, ITT induced a defined increase in plasma concentrations of adrenaline, noradrenaline, growth hormone (GH), and prolactin in the placebo condition.
2.Selective Inhibition of Orexin-2 Receptors Prevents Stress-Induced ACTH Release in Mice.
Yun S;Wennerholm M;Shelton JE;Bonaventure P;Letavic MA;Shireman BT;Lovenberg TW;Dugovic C Front Behav Neurosci. 2017 May 8;11:83. doi: 10.3389/fnbeh.2017.00083. eCollection 2017.
Orexins peptides exert a prominent role in arousal-related processes including stress responding, by activating orexin-1 (OX1R) and orexin-2 (OX2R) receptors located widely throughout the brain. Stress or orexin administration stimulates hyperarousal, adrenocorticotropic hormone (ACTH) and corticosterone release, and selective OX1R blockade can attenuate several stress-induced behavioral and cardiovascular responses but not the hypothalamic-pituitary-adrenal (HPA) axis activation. As opposed to OX1R, OX2R are preferentially expressed in the paraventricular hypothalamic nucleus which is involved in the HPA axis regulation. In the present study, we investigated the effects of a psychological stress elicited by cage exchange (CE) on ACTH release in two murine models (genetic and pharmacological) of selective OX2R inhibition. CE-induced stress produced a significant increase in ACTH serum levels. Mice lacking the OX2R exhibited a blunted stress response. Stress-induced ACTH release was absent in mice pre-treated with the selective OX2R antagonist JNJ-42847922 (30 mg/kg po), whereas pre-treatment with the dual OX1/2R antagonist SB-649868 (30 mg/kg po) only partially attenuated the increase of ACTH.
3.Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ;Renger JJ Br J Pharmacol. 2014 Jan;171(2):283-93. doi: 10.1111/bph.12261.
Insomnia persistently affects the quality and quantity of sleep. Currently approved treatments for insomnia primarily target γ-aminobutyric acid-A (GABA-A) receptor signalling and include benzodiazepines and GABA-A receptor modulators. These drugs are used to address this sleep disorder, but have the potential for side effects such as tolerance and dependence, making them less attractive as maintenance therapy. Forward and reverse genetic approaches in animals have implicated orexin signalling (also referred to as hypocretin signalling) in the control of vigilance and sleep/wake states. Screening for orexin receptor antagonists using in vitro and in vivo methods in animals has identified compounds that block one or other of the orexin receptors (single or dual orexin receptor antagonists [SORAs and DORAs], respectively) in animals and humans. SORAs have primarily been used as probes to further elucidate the roles of the individual orexin receptors, while a number of DORAs have progressed to clinical development as pharmaceutical candidates for insomnia. The DORA almorexant demonstrated significant improvements in a number of clinically relevant sleep parameters in animal models and in patients with insomnia but its development was halted.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Orexin Receptor (OX Receptor) Products

CAS 916141-36-1 TCS 1102

TCS 1102
(CAS: 916141-36-1)

TCS 1102 is a potent, dual orexin receptor antagonist with Ki values of 0.2 and 3 nM for OX2 and OX1 receptors respectively. It is a poor substrate for P-glycop...

CAS 532932-99-3 [Ala11,D-Leu15]-Orexin B

[Ala11,D-Leu15]-Orexin B
(CAS: 532932-99-3)

[Ala11,D-Leu15]-Orexin B is a selective OX2 receptor agonist with EC50 values are 0.13nM for human OX2.

CAS 205640-90-0 Orexin A (human, rat, mouse)

Orexin A (human, rat, mouse)
(CAS: 205640-90-0)

An orexin receptors agonist. It can stimulate feeding following central administration.

CAS 1610882-30-8 TCS-OX2-29 HCl

TCS-OX2-29 HCl
(CAS: 1610882-30-8)

TCS-OX2-29, also known as TCSOX229, is a selective OX2 receptor antagonist (IC50 = 40 nM, pKi = 7.5) with >250-fold selectivity for hOX2R compared with hOX1R (I...

CAS 1369764-02-2 Lemborexant

Lemborexant
(CAS: 1369764-02-2)

Lemborexant, an orexin OX1/OX2 receptors antagonist, has been found to be effective against insomnia and is just planed a Phase III trail by Eisai.

Filorexant
(CAS: 1088991-73-4)

Filorexant, a selective reversible and orally bioavaliable antagonist of OX(1)R receptor and OX(2)R receptor, could probably be an effective compound in the tre...

Orexin 2 Receptor Agonist
(CAS: 1796565-52-0)

N-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide is an orexin 2 receptor agonist that is potentially for...

CAS 483313-22-0 SB-674042

SB-674042
(CAS: 483313-22-0)

SB-674042 is potent and selective non-peptide orexin OX1 receptor antagonist (Kd = 3.76 nM), by binding with high affinity to OX1R and mediates intracellular ca...

Chemical Structure

CAS 380899-24-1 SB-649868

Quick Inquiry

Verification code

Featured Items